Literature DB >> 29378906

Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.

Ken-Ichi Takayama1, Takashi Suzuki2, Tetsuya Fujimura3, Satoru Takahashi4, Satoshi Inoue5,6.   

Abstract

Ubiquitin-specific protease 10 (USP10) is known to deubiquitylate its target proteins, mainly to enhance their stabilities. USP10 maintains p53 protein levels and controls epigenetic changes induced by the androgen receptor (AR). GTPase-activating protein-binding protein 2 (G3BP2), an androgen-responsive gene, is known as the main component of stress granules (SG) that interacts with USP10 in SGs. This study explores the roles of USP10 in prostate cancer progression in p53, G3BP2, and AR signaling. Using chromatin immunoprecipitation (ChIP) and sequence analysis, it was found that USP10 is transcriptionally induced with AR recruitment to an intronic region. Furthermore, USP10 regulates androgen-mediated signaling and cell growth. USP10 maintained G3BP2 protein stability by reducing polyubiquitylation. G3BP2-dependent growth activation and p53 nuclear export that reduced p53 signaling were repressed by USP10 knockdown. Clinically, USP10 was expressed primarily in the cytoplasm of prostate cancer tissues. High levels of USP10 expression were strongly correlated with high levels of AR, G3BP2, and p53 in the cytoplasm. High expression of USP10 was significantly associated with poor prognosis of patients with prostate cancer. Taken together, USP10 has a repressive effect on p53 signaling for cell growth by regulating G3BP2 expression. These findings highlight an important oncogenic aspect of USP10 through its modulation of the p53-G3BP2 complex and AR signaling in prostate cancer.Implications: These findings elucidate the oncogenic role of USP10 in prostate cancer through an increase in G3BP2 protein that inhibits p53 activity, in addition to the promotion of AR signaling. Mol Cancer Res; 16(5); 846-56. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378906     DOI: 10.1158/1541-7786.MCR-17-0471

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  21 in total

1.  USP10 Inhibits Aberrant Cytoplasmic Aggregation of TDP-43 by Promoting Stress Granule Clearance.

Authors:  Masahiko Takahashi; Hiroki Kitaura; Akiyoshi Kakita; Taichi Kakihana; Yoshinori Katsuragi; Osamu Onodera; Yuriko Iwakura; Hiroyuki Nawa; Masaaki Komatsu; Masahiro Fujii
Journal:  Mol Cell Biol       Date:  2022-01-10       Impact factor: 5.069

2.  Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression.

Authors:  Jennifer M Noto; Kristie L Rose; Amanda J Hachey; Alberto G Delgado; Judith Romero-Gallo; Lydia E Wroblewski; Barbara G Schneider; Shailja C Shah; Timothy L Cover; Keith T Wilson; Dawn A Israel; Juan Carlos Roa; Kevin L Schey; Yana Zavros; M Blanca Piazuelo; Richard M Peek
Journal:  Mol Cell Proteomics       Date:  2018-11-19       Impact factor: 5.911

Review 3.  Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.

Authors:  Dominik Awad; Thomas L Pulliam; Chenchu Lin; Sandi R Wilkenfeld; Daniel E Frigo
Journal:  Curr Opin Pharmacol       Date:  2018-03-30       Impact factor: 5.547

4.  Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Doo Byung Chay; Joo Mi Yi; Hanbyoul Cho; Joon-Yong Chung; Jae-Hoon Kim
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

Review 5.  Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.

Authors:  Shiyao Chen; Yunqi Liu; Huchen Zhou
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

6.  Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.

Authors:  Karolina Sienkiewicz; Chunsong Yang; Bryce M Paschal; Aakrosh Ratan
Journal:  Prostate       Date:  2021-12-24       Impact factor: 4.104

7.  The Prognostic Value and Immune Infiltration of USP10 in Pan-Cancer: A Potential Therapeutic Target.

Authors:  Dacheng Gao; Zhiwen Zhang; Rui Xu; Ziyang He; Fangyi Li; Yan Hu; Hui Chen; Jiawei Lu; Xingguo Cao; Yali Liu; Zengguang Xu
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

8.  Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.

Authors:  Alicia de Las Pozas; Teresita Reiner; Virginia De Cesare; Matthias Trost; Carlos Perez-Stable
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

9.  The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.

Authors:  Chen Hu; Mu Zhang; Niko Moses; Cong-Li Hu; Lisa Polin; Wei Chen; Hyejeong Jang; Joshua Heyza; Agnes Malysa; Joseph A Caruso; Shengyan Xiang; Steve Patrick; Paul Stemmer; Zhenkun Lou; Wenlong Bai; Chuangui Wang; Gerold Bepler; Xiaohong Mary Zhang
Journal:  Cell Death Dis       Date:  2020-05-07       Impact factor: 9.685

Review 10.  Rasputin a decade on and more promiscuous than ever? A review of G3BPs.

Authors:  Umber Alam; Derek Kennedy
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-05       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.